Premier of South Australia Steven Marshall Briefed on $50 billion Clinical Trial Sector During Visit to Adelaide-based Avance Clinical

June 1, 2020

The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan.

Adelaide, Australia – The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan. https://ww2.frost.com/news/demand-for-cros-rises-to-strike-evolving-clinical-trial-models-for-target-therapies/

Avance Clinical manages biotech clinical trials in Australia, from its headquarters in South Australia, working with hundreds of clinics and research teams around the country to assess new drugs for regulatory approval that could make a real difference to people’s lives.

The Premier toured the facility in Thebarton and took a briefing on the sector from Avance CEO Yvonne Lungershausen and her team.

Avance Clinical CEO Yvonne Lungershausen said:

“Most of Avance Clinical’s biotech clients are from the USA while numbers from the EU and Asia are on the increase, particularly from China and South Korea.

Australia is a well-established location for international clinical trials and our management of the COVID-19 crisis has made it an even more attractive trials destination.

South Australia has managed the COVID-19 pandemic extremely well, allowing Avance Clinical to continue operations throughout the crisis. However, in other countries clinical trials have been suspended or closed, putting extreme pressure on the biotech sector.”

There are currently 764 clinical studies underway or planned in South Australia alone and a total of 2,225 in Australia.” (ClinicalTrials.Gov)

Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with more than 20-years of experience in managing early phase trials.

In addition to the impressive COVID-19 management, a key factor in sponsor demand is the speed, and attractive cost of running trials in Australia including:

Watch video – how we work during the COVID-19 pandemic here. https://www.avancecro.com/news/news-about-avance-clinical-covid-19-capabilities/

Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.

Register for the Biospectrum Asia and Avance Clinical Webinar here. https://biospectrumasia.com/avance-webinar

For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Adelaide-based Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.

The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:

  1. The Government R&D grant means more than 40% rebate on clinical trial spend
  2. Telehealth pivot during COVID-19 pandemic – speed and continuity
  3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
  4. No IND required for clinical trials
  5. Full GMP material is not mandated for Phase I clinical trials 
  6. Established clinical trial environment with world-class Investigators and sites
  7. Established healthy subject databases and specialised patient populations
  8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
  9. Major hospitals with world class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
  10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons
All Blog Posts